Global Gastro Esophageal Reflux Disease (GERD) Drug Market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030 from USD 2.4 billion in 2018. The market is driven by factors such as increasing prevalence of GERD, rising awareness about GERD and its treatment, and growing geriatric population worldwide. The global gastro esophageal reflux disease (GERD) drug market is segmented on the basis of type into H2 receptor antagonist, proton pump inhibitor (PPi), and antacids; application into hospital, clinic, medical center; and region into North America, Latin America, Europe, Asia Pacific and Middle East & Africa. The H2 receptor antagonist segment accounted for the largest share in 2018 due to its wide range of applications such as relief from heartburn symptoms or acid indigestion caused by stomach acid coming up into the esophagus or throat; prevention of ulcers caused by stomach acid coming up into the esophagus or throat; relief from heartburn symptoms or acid indigestion caused by stomach acid coming up into the esophagus or throat during pregnancy; prevention of ulcers caused by stomach acid coming up into the esophagus or throat during pregnancy; relief from heartburn symptoms or acid indigestion caused by stomach acid coming up through a hiatus hernia that has been surgically repaired with an operation called Nissen fundoplication surgery; prevention of ulcers caused by stomach acids that come up through a hiatus hernia that has been surgically repaired with an operation called Nissen fundoplication surgery. -GERD can lead to complications such as Barrett's Esophagus (a precancerous condition), ulcers in the esophagus or stomach, and strictures (scar tissue) in the esophagus. -There are many treatments for GERD including lifestyle changes such as losing weight or avoiding certain foods; medications; surgery; or a combination of these treatments.
Industry Growth Insights published a new data on “Gastro Esophageal Reflux Disease (GERD) Drug Market”. The research report is titled “Gastro Esophageal Reflux Disease (GERD) Drug Market research by Types (H2 Receptor Antagonist, Proton Pump Inhibitor (PPi), Antacids), By Applications (Hospital, Clinic, Medical Center, Others), By Players/Companies Pfizer, Novartis AG, GlaxoSmithKline, Merck, Medtronic”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gastro Esophageal Reflux Disease (GERD) Drug Market Research Report
By Type
H2 Receptor Antagonist, Proton Pump Inhibitor (PPi), Antacids
By Application
Hospital, Clinic, Medical Center, Others
By Companies
Pfizer, Novartis AG, GlaxoSmithKline, Merck, Medtronic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Gastro Esophageal Reflux Disease (GERD) Drug Market Report Segments:
The global Gastro Esophageal Reflux Disease (GERD) Drug market is segmented on the basis of:
Types
H2 Receptor Antagonist, Proton Pump Inhibitor (PPi), Antacids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Medical Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis AG
- GlaxoSmithKline
- Merck
- Medtronic
Highlights of The Gastro Esophageal Reflux Disease (GERD) Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- H2 Receptor Antagonist
- Proton Pump Inhibitor (PPi)
- Antacids
- By Application:
- Hospital
- Clinic
- Medical Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gastro Esophageal Reflux Disease (GERD) Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gastroesophageal reflux disease (GERD) is a condition in which the stomach's acid and digestive juices flow back up into the esophagus, causing heartburn. This can be a problem when eating or drinking. Some people also have difficulty swallowing because of GERD.
Some of the major players in the gastro esophageal reflux disease (gerd) drug market are Pfizer, Novartis AG, GlaxoSmithKline, Merck, Medtronic.
The gastro esophageal reflux disease (gerd) drug market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gastro Esophageal Reflux Disease (GERD) Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gastro Esophageal Reflux Disease (GERD) Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gastro Esophageal Reflux Disease (GERD) Drug Market - Supply Chain
4.5. Global Gastro Esophageal Reflux Disease (GERD) Drug Market Forecast
4.5.1. Gastro Esophageal Reflux Disease (GERD) Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gastro Esophageal Reflux Disease (GERD) Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gastro Esophageal Reflux Disease (GERD) Drug Market Absolute $ Opportunity
5. Global Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Type
5.3.1. H2 Receptor Antagonist
5.3.2. Proton Pump Inhibitor (PPi)
5.3.3. Antacids
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Medical Center
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gastro Esophageal Reflux Disease (GERD) Drug Demand Share Forecast, 2019-2026
9. North America Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Medical Center
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Type
9.7.1. H2 Receptor Antagonist
9.7.2. Proton Pump Inhibitor (PPi)
9.7.3. Antacids
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gastro Esophageal Reflux Disease (GERD) Drug Demand Share Forecast, 2019-2026
10. Latin America Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Medical Center
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Type
10.7.1. H2 Receptor Antagonist
10.7.2. Proton Pump Inhibitor (PPi)
10.7.3. Antacids
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gastro Esophageal Reflux Disease (GERD) Drug Demand Share Forecast, 2019-2026
11. Europe Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Medical Center
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Type
11.7.1. H2 Receptor Antagonist
11.7.2. Proton Pump Inhibitor (PPi)
11.7.3. Antacids
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gastro Esophageal Reflux Disease (GERD) Drug Demand Share, 2019-2026
12. Asia Pacific Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Medical Center
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Type
12.7.1. H2 Receptor Antagonist
12.7.2. Proton Pump Inhibitor (PPi)
12.7.3. Antacids
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gastro Esophageal Reflux Disease (GERD) Drug Demand Share, 2019-2026
13. Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Medical Center
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Market Size and Volume Forecast by Type
13.7.1. H2 Receptor Antagonist
13.7.2. Proton Pump Inhibitor (PPi)
13.7.3. Antacids
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Gastro Esophageal Reflux Disease (GERD) Drug Market: Market Share Analysis
14.2. Gastro Esophageal Reflux Disease (GERD) Drug Distributors and Customers
14.3. Gastro Esophageal Reflux Disease (GERD) Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis AG
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Medtronic
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook